Close Menu

NEW YORK — Co-Diagnostics on Thursday reported first quarter 2020 revenues of $1.5 million, up from $3,400 the year before, primarily due to sales the company's recently launched Logix Smart COVID-19 test for SARS-CoV-2.

Since the commercial launch of Logix Smart COVID-19 in March, Co-Diagnostics has manufactured more than six million tests and recorded COVID-19-related test and equipment sales of over $18 million. The Salt Lake City-based company added that it has also ordered components for more than 20 million additional tests to fill existing and expected orders.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.